Daniel Tripodi
Executive Director

  • Ph.D. in Immunochemistry from Temple University.

  • Senior positions in R&D, Marketing, Technological and Strategic Planning at  Johnson & Johnson.

  • Director of Technical Planning at Becton-Dickinson.

  • General Manager of the Biomedical Division at New England Nuclear.

  • Scientific Advisory Boards of the State University of New York at Stony Brook and the University of Utah.

  • Trustee of Federal Trade Commission.
     

Daniel Tripodi, Ph.D. -- Having been formally trained in the sciences, throughout his career Dr. Tripodi has interfaced between emerging technologies and their translation into business opportunities. As a partner with Owen, Pambianchi & Associates, he has served a variety of biomedical and biopharmaceutical companies in the areas of technology assessment, business and technology development strategy and new venture formation.  Prior to this activity, Dr. Tripodi started a successful consulting company, Tricon Associates, which was merged in 1992 into Owen, Pambianchi.  Tricon assisted in the start-up of several new entities, including Fibritek, for which Dr. Tripodi served as President and CEO in 1991. Tricon's major focus was to identify new technology, usually from universities, and position them either as transfers to existing companies, or as the basis for new entities.  Clients included many academic and research institutions throughout the country.  

Most of Dr. Tripodi's industrial career was with Johnson & Johnson.  During his approximately 20 years there, he held various senior positions in R&D, Marketing, Technological and Strategic Planning at both the divisional and corporate levels.  He was instrumental in establishing several new entities within Johnson & Johnson and was involved in setting up the Scripps/J&J collaborative effort, and headed the original J&J division established to develop technology emanating from Scripps.  

His career also included positions at Becton-Dickinson, as Director of Technical Planning, and at New England Nuclear, as General Manager of the Biomedical Division.  He has published extensively in the fields of immunochemistry and immunology, and holds several patents, for both drugs and devices.

Since obtaining his Ph.D. in Immunochemistry from Temple University, he has continued to maintain academic appointments at Temple University, University of Pennsylvania and the University of Delaware.

He also serves on Scientific Advisory Boards of the State University of New York at Stony Brook and the University of Utah, as well as the Biotechnology Advisory Committee for the Department of Commerce and the Immunodiagnostic Committee of the National Committee of Clinical Laboratory Standards.